Wednesday, October 31, 2018

Axial Biotherapeutics Names New CFO, VP

Pasadena-based Axial Biotherapeutics, which is developing treatments for neurological diseases, said yesterday that it has named Jeffrey Young as its first Chief Financial Officer (CFO), and appointed Dennis Yamashita, Ph.D., as Vice President, Medicinal Chemistry. Young was most recently CFO, Treasurer, and Secretary at Juniper Pharmaceuticals, and also served at OvaScience, Transmedics, Lantheus Medical Imaging, Critical Therapeutics, PerkinElmer, and PriceWaterhouseCoopers LLP. Yamashita was most recently VP Drug Discovery of ORIC (Overcoming Resistance in Cancer), and also had served at GSK and Trevena.